Glepaglutide

China [CN]

Glepaglutide is an investigational long-acting glucagon-like peptide-2 (GLP-2) analog being developed for the treatment of short bowel syndrome (SBS). It works by binding to and activating GLP-2 receptors in the intestines, which increases the absorption of fluids and nutrients and reduces fecal output. Administered as a subcutaneous injection, glepaglutide has a long half-life of approximately 88 hours, which allows for less frequent dosing (e.g., twice weekly) compared to other GLP-2 analogs. Common side effects include stoma complications, injection site reactions, peripheral edema, nausea, abdominal pain, and fatigue. As of 2026, glepaglutide is pending regulatory approval in the United States.